Edition:
India

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.68USD
1:30am IST
Change (% chg)

$-0.05 (-6.47%)
Prev Close
$0.73
Open
$0.75
Day's High
$0.75
Day's Low
$0.65
Volume
1,890,182
Avg. Vol
363,600
52-wk High
$3.41
52-wk Low
$0.65

Select another date:

Mon, Apr 16 2018

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Select another date: